1-9 of 9
Ajeeta B Dash, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva, PhD, Irene Manrique, PhD, Nicola Giuliani, Michele Cavo, Christine Rojas, MD, Weijun Fu, MD PhD, María-Victoria Mateos, MD PhD, Meletios A Dimopoulos, Alexander Vorog, MD, Cong Li, PhD, Bingxia Wang, PhD, Richard J Labotka, MD, Ajeeta B Dash, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-136105
Published: 2020
Journal Articles

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Soo Park, MD, Brian M Reilly, BS, Timothy Luger, Dan Zhao, Robert J. Fram, MD, Ajeeta B Dash, PhD, Rafael Bejar, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-134484
Published: 2020
Journal Articles

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MDMSc, Wenrou Zheng, MSc, Jack P. Higgins, PhD, Erin K. Willert, PhD, John Newcomb, PhD, Ajeeta B Dash, PhD, Niels W.C.J. Van De Donk, MD PhD, Sonja Zweegman, MDPhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136928
Published: 2020
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019
Journal Articles

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Bin Li, PhD, Kaili Ren, PhD, Lei Shen, PhD, Peijie Hou, PhD, Zhenqiang Su, PhD, Alessandra Di Bacco, PhD, Jin-Liern Hong, PhD, Aaron Galaznik, PhD, Ajeeta B Dash, PhD, Victoria Crossland, PhD, Paul Dolin, DPhil, Sandor Szalma, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3298.
https://doi.org/10.1182/blood-2018-99-115017
Published: 2018
Journal Articles

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 473.
https://doi.org/10.1182/blood-2018-99-114614
Published: 2018
Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos, MD, Francesca Gay, MDPhD, Fredrik H. Schjesvold, MDPhD, Meral Beksac, MD, Roman Hajek, Katja Weisel, MD, Hartmut Goldschmidt, MD, Vladimir Maisnar, MD, Philippe Moreau, Chang-Ki Min, MD PhD, Agnieszka Pluta, MD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Martin Kaiser, MD, Sonja Zweegman, MDPhD, Maria-Victoria Mateos, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shinsuke Iida, MDPhD, Gareth Morgan, MD, Zhaoyang Teng, PhD, Kaveri Suryanarayan, MD, Tomas Skacel, MD PhD, Ajeeta B Dash, PhD, Richard Labotka, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 301.
https://doi.org/10.1182/blood-2018-99-112079
Published: 2018
Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD
Journal: Blood
Blood (2016) 128 (22): 98.
https://doi.org/10.1182/blood.V128.22.98.98
Published: 2016
Journal Articles

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Ronan T Swords, MD PhD FRCPI, FRCPath, Michael R Savona, MD, Michael B Maris, MD, Harry P Erba, MD PhD, Jesus G. Berdeja, MD, James M. Foran, MD, Zhaowei Hua, PhD, Hélène M Faessel, PharmD, PhD, Ajeeta B Dash, PhD, Farhad Sedarati, PhD, Bruce J Dezube, MD, Bruno C Medeiros, MD
Journal: Blood
Blood (2014) 124 (21): 2313.
https://doi.org/10.1182/blood.V124.21.2313.2313
Published: 2014